Analysis
Edwards Lifesciences has reported a manageable impact from the U.S. tariffs introduced in April 2025 (often referred to as 'Liberation Day' tariffs). The company’s CFO, Scott Ullem, quantified the net impact of the 10% baseline reciprocal tariffs at approximately $0.05 per share for fiscal year 2025. This equates to a total cost headwind of approximately $30 million for the year. The impact was relatively limited because the company maintains a significant portion of its manufacturing operations within the United States and has strategically located facilities in other key business regions, which helps buffer against import duties.
While the company acknowledged the immediate pressure on operating margins, management successfully absorbed these costs within their existing 2025 financial guidance. Throughout the year, Edwards actually raised its sales and earnings guidance multiple times, driven by strong procedural growth in its core TAVR and TMTT segments, which suggests that the tariffs did not significantly dampen demand or commercial momentum. The gross margin decline observed in 2025 (approximately 150 basis points) was attributed primarily to manufacturing expenses related to the expansion of new therapies and foreign exchange, rather than being dominated by tariff costs.
Looking forward to 2026, management has cautioned that the impact of tariffs could increase as the full-year effect of the trade policies is realized. CFO Scott Ullem noted in early 2025 that a 'bigger impact' was likely in 2026, although the company has not yet provided a specific dollar quantification for the upcoming year. Despite this potential headwind, Edwards has issued 2026 guidance that anticipates continued margin expansion and double-digit earnings growth, indicating that ongoing supply chain mitigation strategies and the launch of higher-margin therapies (such as the SAPIEN M3 and EVOQUE platforms) are expected to more than offset the incremental tariff burden.
The company continues to monitor U.S. trade policy closely, noting that its current guidance assumes existing tariffs remain in place. Edwards has signaled its intent to pursue further mitigation options as needed, including potential exemptions, exclusions, and supply chain adjustments to minimize long-term exposure to import duties. Significant litigation expenses reported in late 2025 were clarified as being related to a major intellectual property settlement with Medtronic and unrelated tax litigation, rather than tariff-related legal disputes.
Data
($ in millions, except per share data)
| Metric | FY 2025 Impact |
|---|---|
| Estimated Adjusted EPS Impact | ($0.05) |
| Estimated Net Cost Impact (Total Company) | ($29.3) – ($30.0) |
| Net Sales (FY 2025) | $6,067.6 |
| Adjusted Operating Margin (FY 2025) | 27.1% |
Source: FY-2025 Annual Report, FY-2025 Transcript, MedTech Dive
Financial Impact
- Cost Impact (Historic): $30M
Sources
CFO Scott Ullem pegged the impact from the Trump administration’s 10% baseline tariffs on per-share earnings at 5 cents this year.
Edwards' guidance reflects the Company's current estimates of the impact from tariffs that are in effect or have been announced as of the time of this press release and assumes such tariffs remain in place for the remainder of 2025.
We may not be as complex as some others because we operate just a handful of production facilities that are strategically located within our key business regions.